Get started
Author

Shinsuke Ogusu

Observed names: S. Ogusu, SHINSUKE OGUSU
Institution: Saga University
ORCID: 0000-0001-5185-6907
Observed ORCID: 0000-0001-5185-6907
OpenAlex ID: A5081135872
Discontinuation due to immune‐related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non‐small cell lung cancer
2019 · Kazutoshi Komiya, Tomomi Nakamura, et al. · Thoracic Cancer · 59
PDF
Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with GenexusTM integrated sequencer
2022 · Siew-Kee Low, Ryo Ariyasu, et al. · Translational Lung Cancer Research · 33
PDF
Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice
2020 · Ryo Ariyasu, Ken Uchibori, et al. · Thoracic Cancer · 26
PDF
Impact of Renin–angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients
2021 · TAKEHIRO TOZUKA, NORIKO YANAGITANI, et al. · Anticancer Research · 21
PDF
Current Status and Problems of T790M Detection, a Molecular Biomarker of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy
2018 · KAZUTOSHI KOMIYA, CHIHO NAKASHIMA, et al. · Anticancer Research · 16
PDF
Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer
2023 · Shinsuke Ogusu, Yuhei Harutani, et al. · Cancer Immunology Immunotherapy · 15
PDF
A rare case of Trichosporon mycotoxinivorans and Cryptococcus neoformans co-infection in lung
2020 · Hironori Sadamatsu, Koichiro Takahashi, et al. · Journal of Infection and Chemotherapy · 12
Primary Pulmonary Colloid Adenocarcinoma: How Can We Obtain a Precise Diagnosis?
2018 · Shinsuke Ogusu, Koichiro Takahashi, et al. · Internal Medicine · 11
PDF
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study
2025 · Kenji Morimoto, Tadaaki Yamada, et al. · Lung Cancer · 8
Factors related to the diagnosis of lung cancer by transbronchial biopsy with endobronchial ultrasonography and a guide sheath
2022 · Yuki Kurihara, Hiroki Tashiro, et al. · Thoracic Cancer · 7
PDF
Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib
2021 · Hiroaki Sakamoto, Noriko Yanagitani, et al. · Cancer Reports · 7
PDF
Sjögren Syndrome Complicated with Cystic Lung Disease and Pulmonary Amyloidosis
2018 · Koichiro Takahashi, Hironori Sadamatsu, et al. · Case Reports in Rheumatology · 6
PDF
Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2
2021 · Ken Uchibori, Natsuki Takano, et al. · Thoracic Cancer · 4
Signet Ring Cell Carcinoma of Unknown Primary Complicated with Pulmonary Tumor Thrombotic Microangiopathy and Krukenberg Tumor
2018 · Masahide Tanaka, Koichiro Takahashi, et al. · Case Reports in Oncology · 4
PDF
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1–49 %): TOPGAN2023-01
2024 · Hisashi Tanaka, Tomonori Makiguchi, et al. · European Journal of Cancer · 3
PDF
Efficacy of osimertinib in patients with EGFR ‐mutation positive non‐small cell lung cancer with malignant pleural effusion
2024 · Ayu Kiritani, Yoshiaki Amino, et al. · Thoracic Cancer · 3
PDF
Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients
2023 · Takehiro Tozuka, Noriko Yanagitani, et al. · Investigational New Drugs · 3
Usefulness of blood biomarkers for predicting venous thromboembolism in Japanese patients with cancer
2023 · Yohei Harada, Akemi Sato, et al. · Oncology Letters · 3
PDF
EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy
2022 · Shinsuke Ogusu, Ryo Ariyasu, et al. · Investigational New Drugs · 3
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non–small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102)
2025 · Yoshimasa Shiraishi, Takayuki Shimose, et al. · European Journal of Cancer · 2
PDF
Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure
2025 · Kenji Morimoto, Tadaaki Yamada, et al. · Targeted Oncology · 2
Toxocariasis presenting with peripheral eosinophilia and eosinophilic pleural effusion: A case report
2026 · Mizuki Nanri, Hiroki Tashiro, et al. · Journal of Infection and Chemotherapy · 1
1010P Observational study to investigate the safety and effectiveness of first-line lorlatinib in patients with ALK gene–rearranged unresectable advanced/recurrent non-small cell lung cancer in real-world clinical settings in Japan
2025 · M. Nishio, E. Miyauchi, et al. · Annals of Oncology · 1
Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study
2025 · Kenji Morimoto, Tadaaki Yamada, et al. · International Journal of Clinical Oncology · 1
Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression
2025 · K. Morimoto, T. Yamada, et al. · ESMO Real World Data and Digital Oncology · 1
PDF
Works count: 48
Citation count: 255
H-index: 8
I10-index: 8
Year
Topic
Type